Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 73 articles:
HTML format
Text format



Single Articles


    April 2017
  1. CHRISTIE EL, Fereday S, Doig K, Pattnaik S, et al
    Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer.
    J Clin Oncol. 2017;35:1274-1280.
    PubMed     Text format     Abstract available


  2. KONECNY GE
    Understanding Exceptional Responses to Poly (ADP-ribose) Polymerase Inhibition in Sporadic Ovarian Cancer.
    J Clin Oncol. 2017;35:1151-1153.
    PubMed     Text format    


  3. TAYLOR JS, Rajan SS, Zhang N, Meyer LA, et al
    End-of-Life Racial and Ethnic Disparities Among Patients With Ovarian Cancer.
    J Clin Oncol. 2017 Apr 7:JCO2016702894. doi: 10.1200/JCO.2016.70.2894.
    PubMed     Text format     Abstract available


    February 2017
  4. ROSENTHAL AN, Fraser LS, Philpott S, Manchanda R, et al
    Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.
    J Clin Oncol. 2017 Feb 27:JCO2016699330. doi: 10.1200/JCO.2016.69.9330.
    PubMed     Text format     Abstract available


    January 2017
  5. FOTOPOULOU C, Sehouli J, Aletti G, Harter P, et al
    Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective.
    J Clin Oncol. 2017 Jan 9:JCO2016710723.
    PubMed     Text format    


    December 2016
  6. RUTTEN MJ, van Meurs HS, van de Vrie R, Gaarenstroom KN, et al
    Laparoscopy to Predict the Result of Primary Cytoreductive Surgery in Patients With Advanced Ovarian Cancer: A Randomized Controlled Trial.
    J Clin Oncol. 2016 Dec 28:JCO2016692962.
    PubMed     Text format     Abstract available


  7. COPUR MS, Gauchan D, Ramaekers R, Crockett D, et al
    Neoadjuvant Chemotherapy or Primary Debulking Surgery for Stage IIIC Ovarian Cancer.
    J Clin Oncol. 2016 Dec 28:JCO2016707125.
    PubMed     Text format    


  8. LIU JF, Ray-Coquard I, Selle F, Poveda AM, et al
    Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.
    J Clin Oncol. 2016;34:4345-4353.
    PubMed     Text format     Abstract available


  9. SCHRAM AM, Iasonos A, Hyman DM
    Picking the Right Patient for Human Epidermal Growth Factor Receptor 3-Targeted Therapy in Platinum-Resistant Ovarian Cancer.
    J Clin Oncol. 2016;34:4312-4314.
    PubMed     Text format    


  10. LEIJEN S, van Geel RM, Sonke GS, de Jong D, et al
    Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.
    J Clin Oncol. 2016;34:4354-4361.
    PubMed     Text format     Abstract available


    September 2016
  11. MEYER LA, Cronin AM, Sun CC, Bixel K, et al
    Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer.
    J Clin Oncol. 2016 Sep 6. pii: JCO681239.
    PubMed     Text format     Abstract available


    August 2016
  12. WRIGHT AA, Bohlke K, Armstrong DK, Bookman MA, et al
    Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.
    J Clin Oncol. 2016 Aug 8. pii: JCO686907.
    PubMed     Text format     Abstract available


    June 2016
  13. WENTZENSEN N, Poole EM, Trabert B, White E, et al
    Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium.
    J Clin Oncol. 2016 Jun 20. pii: JCO668178.
    PubMed     Text format     Abstract available


  14. KURZEDER C, Bover I, Marme F, Rau J, et al
    Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE).
    J Clin Oncol. 2016 Jun 6. pii: JCO660787.
    PubMed     Text format     Abstract available


    May 2016
  15. ABDERRAHMAN B, Jordan VC
    Estrogen Deprivation Therapy in Ovarian Cancer: An Opportunity.
    J Clin Oncol. 2016 May 23. pii: JCO673137.
    PubMed     Text format    


    March 2016
  16. KILICKAP S, Tural D
    Does Adjuvant Hormone Therapy Improve Survival in Epithelial Ovarian Cancer?
    J Clin Oncol. 2016 Mar 21. pii: JCO653683.
    PubMed     Text format    


  17. VOUTSADAKIS IA
    On Adjuvant Hormone Therapy in Epithelial Ovarian Cancer.
    J Clin Oncol. 2016 Mar 21. pii: JCO663245.
    PubMed     Text format    


  18. VERGOTE I, Armstrong D, Scambia G, Teneriello M, et al
    A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse.
    J Clin Oncol. 2016 Mar 21. pii: JCO632596.
    PubMed     Text format     Abstract available


  19. WRIGHT AA, Cronin A, O'Malley DM
    Reply to G.B. Holt.
    J Clin Oncol. 2016;34:1016-7.
    PubMed     Text format    


  20. TUNG N, Lin NU, Kidd J, Allen BA, et al
    Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.
    J Clin Oncol. 2016 Mar 14. pii: JCO650747.
    PubMed     Text format     Abstract available


  21. CHAN JK, Monk BJ
    Reply to F.M. Muggia.
    J Clin Oncol. 2016;34:882-3.
    PubMed     Text format    


  22. BOOKMAN MA, Brady MF
    Reply to F.M. Muggia.
    J Clin Oncol. 2016;34:884.
    PubMed     Text format    


  23. SCHRADER KA, Stratton KL, Murali R, Laitman Y, et al
    Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant.
    J Clin Oncol. 2016;34:e61-7.
    PubMed     Text format    


    February 2016
  24. LOPES LF, Macedo CR, Aguiar Sdos S, Barreto JH, et al
    Lowered Cisplatin Dose and No Bleomycin in the Treatment of Pediatric Germ Cell Tumors: Results of the GCT-99 Protocol From the Brazilian Germ Cell Pediatric Oncology Cooperative Group.
    J Clin Oncol. 2016;34:603-10.
    PubMed     Text format     Abstract available


  25. LAMM W, Schiefer A, Nobauer IM, Horvat R, et al
    Aromatase Inhibitor Therapy As Effective Rescue in a Patient With Tamoxifen-Refractory Metastatic Granulosa Cell Tumor of the Ovary.
    J Clin Oncol. 2016;34:e31-3.
    PubMed     Text format    


  26. MUGGIA FM
    Intraperitoneal Therapy for Ovarian Cancer.
    J Clin Oncol. 2016 Feb 1. pii: JCO628370.
    PubMed     Text format    


    January 2016
  27. BOULAY RM
    Beautiful Imperfections.
    J Clin Oncol. 2016;34:286-7.
    PubMed     Text format    


  28. HORN C, Campbell G, Hagan T, Bovbjerg DH, et al
    Associations between peripheral neuropathy and nausea/vomiting in survivors of ovarian cancer: Evidence of persistent vagal neuropathies?
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  29. ANGARITA A, Cristello A, Lippitt M, Nickles Fader A, et al
    The "little big things": A qualitative study of ovarian cancer survivors and their experiences with the health care system.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  30. GASPARRI ML, Crispino S, La Russa C, Marchetti C, et al
    A 10-year age-related survival analysis on cytoreductive surgery in stage IIIC-IV ovarian cancer: Elderly versus younger women.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  31. BLACKMON JE, Recklitis CJ, Wright AA
    Preliminary results from the Sexual Therapy and Rehabilitation after Treatment for Ovarian Cancer (START-OC) study.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  32. HOLT GB
    Potential Simpson's Paradox in Multicenter Study of Intraperitoneal Chemotherapy for Ovarian Cancer.
    J Clin Oncol. 2016 Jan 11. pii: JCO644542.
    PubMed     Text format    


  33. PUJADE-LAURAINE E, Selle F, Weber B, Ray-Coquard IL, et al
    Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study.
    J Clin Oncol. 2016 Jan 11. pii: JCO621474.
    PubMed     Text format     Abstract available


  34. MENON U, Kalsi JK, Gentry-Maharaj A, Ryan A, et al
    Reply to P.F. Pinsky, C.P. Crum, and M.W. McIntosh et al.
    J Clin Oncol. 2016;34:201-2.
    PubMed     Text format    


  35. PINSKY PF
    Definition of Specificity in a Screening Trial.
    J Clin Oncol. 2016;34:198.
    PubMed     Text format    


    November 2015
  36. CRUM CP
    Preventing Ovarian Cancer.
    J Clin Oncol. 2015 Nov 16. pii: JCO.2015.62.9519.
    PubMed     Text format    


  37. MCINTOSH MW, Drescher C, Fitzgibbon MM
    Ovarian Cancer Early Detection Needs Better Imaging, Not Better Algorithms or Biomarkers.
    J Clin Oncol. 2015 Nov 16. pii: JCO.2015.63.7843.
    PubMed     Text format    


    October 2015
  38. HOMICSKO K, Coukos G
    Targeting Programmed Cell Death 1 in Ovarian Cancer.
    J Clin Oncol. 2015 Oct 26. pii: JCO.2015.63.7785.
    PubMed     Text format    


  39. ALETTI GD, Bristow RE, Chi D, Cliby WA, et al
    There Is Nothing New Under the Sun.
    J Clin Oncol. 2015;33:3520.
    PubMed     Text format    


  40. HOROWITZ N, Miller A, Rungruang B, Richard S, et al
    Reply to G.D. Aletti et al.
    J Clin Oncol. 2015;33:3521-2.
    PubMed     Text format    


  41. LIPKOWITZ S, Kohn EC
    To Treat or Not to Treat: The Use of Hormone Replacement Therapy in Patients With Ovarian Cancer.
    J Clin Oncol. 2015 Oct 5. pii: JCO.2015.63.6670.
    PubMed     Text format    


    September 2015
  42. EELES RA, Morden JP, Gore M, Mansi J, et al
    Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial.
    J Clin Oncol. 2015 Sep 28. pii: JCO.2015.60.9719.
    PubMed     Text format     Abstract available


  43. HAMANISHI J, Mandai M, Ikeda T, Minami M, et al
    Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
    J Clin Oncol. 2015 Sep 8. pii: JCO.2015.62.3397.
    PubMed     Text format     Abstract available


    August 2015
  44. GRISHAM RN, Sylvester BE, Won H, McDermott G, et al
    Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.
    J Clin Oncol. 2015 Aug 31. pii: JCO.2015.62.4726.
    PubMed     Text format     Abstract available


  45. GERSHENSON DM, Bodurka DC, Lu KH, Nathan LC, et al
    Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor.
    J Clin Oncol. 2015;33:2675-82.
    PubMed     Text format     Abstract available


  46. PENDLEBURY A, Rischin D, Ireland-Jenkin K, Toner GC, et al
    Ovarian Growing Teratoma Syndrome With Spuriously Elevated alpha-Fetoprotein.
    J Clin Oncol. 2015;33:e99-100.
    PubMed     Text format    


  47. POVEDA AM, Selle F, Hilpert F, Reuss A, et al
    Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial.
    J Clin Oncol. 2015 Aug 17. pii: JCO.2015.63.1408.
    PubMed     Text format    


  48. SONG H, Dicks E, Ramus SJ, Tyrer JP, et al
    Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population.
    J Clin Oncol. 2015 Aug 10. pii: JCO.2015.61.2408.
    PubMed     Text format     Abstract available


  49. WRIGHT AA, Cronin A, Milne DE, Bookman MA, et al
    Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer.
    J Clin Oncol. 2015 Aug 3. pii: JCO.2015.61.4776.
    PubMed     Text format     Abstract available


  50. BOHM S, Faruqi A, Said I, Lockley M, et al
    Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma.
    J Clin Oncol. 2015;33:2457-63.
    PubMed     Text format     Abstract available


    June 2015
  51. HE W, Fang F, Varnum C, Eriksson M, et al
    Predictors of Discontinuation of Adjuvant Hormone Therapy in Patients With Breast Cancer.
    J Clin Oncol. 2015 Jun 1. pii: JCO.2014.59.3673.
    PubMed     Text format     Abstract available


    May 2015
  52. MENON U, Ryan A, Kalsi J, Gentry-Maharaj A, et al
    Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening.
    J Clin Oncol. 2015 May 11. pii: JCO.2014.59.4945.
    PubMed     Text format     Abstract available


  53. MOURITS MJ, de Bock GH, Hollema H
    Pathologic findings at risk-reducing surgery.
    J Clin Oncol. 2015;33:1514.
    PubMed     Text format    


  54. HERZOG TJ, Coleman RL, Monk BJ, Armstrong DK, et al
    In assessing surrogate clinical trial end points: drug safety is a requisite.
    J Clin Oncol. 2015;33:1511-2.
    PubMed     Text format    


    April 2015
  55. SCOTT CL, Swisher EM, Kaufmann SH
    Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.
    J Clin Oncol. 2015;33:1397-406.
    PubMed     Text format     Abstract available


  56. HOSKINS PJ, Fung-Kee-Fung M, Miller D, Gotlieb W, et al
    Time for a Level Playing Field: Inequalities in Regulatory/Approval Processes-The Example of Bevacizumab in Epithelial Ovarian Cancer.
    J Clin Oncol. 2015 Apr 6. pii: JCO.2014.58.3690.
    PubMed     Text format    


    March 2015
  57. TEWARI D, Java JJ, Salani R, Armstrong DK, et al
    Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study.
    J Clin Oncol. 2015 Mar 23. pii: JCO.2014.55.9898.
    PubMed     Text format     Abstract available


    February 2015
  58. HOROWITZ NS, Miller A, Rungruang B, Richard SD, et al
    Does Aggressive Surgery Improve Outcomes? Interaction Between Preoperative Disease Burden and Complex Surgery in Patients With Advanced-Stage Ovarian Cancer: An Analysis of GOG 182.
    J Clin Oncol. 2015 Feb 9. pii: JCO.2014.56.3106.
    PubMed     Text format     Abstract available


    January 2015
  59. KAUFMAN B, Shapira-Frommer R, Schmutzler RK, Audeh MW, et al
    Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
    J Clin Oncol. 2015;33:244-50.
    PubMed     Text format     Abstract available


  60. REDDY AMMAKKANAVAR N, Matei D, Abonour R, Einhorn LH, et al
    High-dose chemotherapy for recurrent ovarian germ cell tumors.
    J Clin Oncol. 2015;33:226-7.
    PubMed     Text format    


    December 2014
  61. COUCH FJ, Hart SN, Sharma P, Toland AE, et al
    Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer.
    J Clin Oncol. 2014 Dec 1. pii: JCO.2014.57.1414.
    PubMed     Text format     Abstract available


    November 2014
  62. KURTA ML, Edwards RP, Moysich KB, McDonough K, et al
    Prognosis and Conditional Disease-Free Survival Among Patients With Ovarian Cancer.
    J Clin Oncol. 2014 Nov 17. pii: JCO.2014.55.1713.
    PubMed     Text format     Abstract available


  63. ESKANDER RN, Chang J, Ziogas A, Anton-Culver H, et al
    Evaluation of 30-Day Hospital Readmission After Surgery for Advanced-Stage Ovarian Cancer in a Medicare Population.
    J Clin Oncol. 2014 Nov 10. pii: JCO.2014.56.7743.
    PubMed     Text format     Abstract available


  64. DANIELS MS, Lu KH
    Reply to D. Braun et al.
    J Clin Oncol. 2014;32:3683.
    PubMed     Text format    


  65. BRAUN D, Gorfine M, Parmigiani G
    Misreported family histories and underestimation of risk.
    J Clin Oncol. 2014;32:3682-3.
    PubMed     Text format    


  66. PUJADE-LAURAINE E, Hilpert F, Poveda A
    Reply to F. Tomao et al.
    J Clin Oncol. 2014;32:3580.
    PubMed     Text format    


    October 2014
  67. SHERMAN ME, Piedmonte M, Mai PL, Ioffe OB, et al
    Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.
    J Clin Oncol. 2014;32:3275-83.
    PubMed     Text format     Abstract available


    September 2014
  68. LHOMME C, Leary A, Uzan C, Pautier P, et al
    Adjuvant chemotherapy in stage I ovarian germ cell tumors: should indications and treatment modalities be different in young girls and adults?
    J Clin Oncol. 2014;32:2815-6.
    PubMed     Text format    


  69. MANGILI G, Sigismondi C, Lorusso D, Pignata S, et al
    Surveillance policy for stage IA malignant ovarian germ cell tumors in children and young adults.
    J Clin Oncol. 2014;32:2814-5.
    PubMed     Text format    


  70. BILLMIRE DF, Krailo M, Rodriguez-Galindo C, Frazier AL, et al
    Reply to G. Mangili et al and C. Lhomme et al.
    J Clin Oncol. 2014;32:2816-7.
    PubMed     Text format    


    August 2014
  71. TEW WP, Muss HB, Kimmick GG, Von Gruenigen VE, et al
    Breast and ovarian cancer in the older woman.
    J Clin Oncol. 2014;32:2553-61.
    PubMed     Text format     Abstract available


  72. FREIDLIN B, Korn EL
    Transparency in interim monitoring.
    J Clin Oncol. 2014;32:2387-8.
    PubMed     Text format    


  73. VERGOTE I, Coens C, Casado A, Jimeno A, et al
    Reply to B. Freidlin et al.
    J Clin Oncol. 2014;32:2388.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: